Bristol-Myers Squibb Company: ONGLYZATM (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes

PARIS & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE/LSE: AZN) announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.